Natixis commits to cancer research
Natixis supports Institut Gustave Roussy’s research program on the personalized treatment of cancer, specifically three teams that are researching cancer proliferation mechanisms.
Natixis supports Institut Gustave Roussy1
The Institute is one of the leading cancer research centers in Europe. Natixis’ support will help attract new talents and advance research towards personalized cancer treatment.
Some patients find themselves at an impasse when standard treatment can no longer help them. Personalized therapy brings new hope. This new approach takes into account the patient’s own characteristics and the specifics of the cancer genome to adjust the treatment.
Three Natixis research teams
As part of its sponsorship, Natixis will support specifically three research teams for the next three years.
The first team, headed by Jean-Luc Perfettini, is researching “Cell death and senescence*”.
The objective of the research is to target cancer cells more precisely during radiation to improve radiotherapy efficiency and patient comfort. Specifically, they wish to determine how radiation causes cell death or senescence and how to make cancer cell more sensitive to radiation.
The second team, headed by Fanny Jaulin, is researching “Epithelial morphogenesis and colon cancer”.
Their research concerns mainly the proliferation and migration of epithelial cells that cause 85% of all cancers. On top of treating colon cancer, which is a real public health issue with 44,000 new cases and 17,000 deaths each year, this research could benefit the research on other pathologies.
The third team, headed by Mehdi Khaled, is researching “Melanoma and tumor invasion”. The melanoma is a dreadful type of cancer because the high risk of cancer metastasis. The research project of Dr. Mehdi Khaled is to identify the genes that are responsible for the development of cancer metastasis and to identify the molecules that can block these genes by way of large scale screening. This research will lead to developing anti-metastasis treatment for the melanoma, which do not exist at this point, and to improving existing therapies.
*physiological aging process (in this particular instance, the aging of cells)
Natixis’ commitment is shared by its staff, who for three years has taken part in the Odysséa race. Registration fees are paid to Institut Gustave Roussy for breast cancer research.
More efficient methods to fight cancer
According to the WHO (World Health Organization), the number of deaths due to cancer should reach 13.1 million in 2030 worldwide versus 7.6 million in 2008.
In France, the number of new cases has practically doubled in 25 years but at the same time the risk of dying of cancer dropped 25% (Source: l'Institut national de veille sanitaire (InVS))
Nowadays, the treatment of people with cancer has greatly improved: better prevention; earlier, more frequent and more specific detection; more precise diagnosis; finally, personalized treatments using one or several techniques (surgery, chemotherapy, radiation therapy and brachytherapy, immunotherapy, transplant). All these treatments are efficient against cancer and give new hope.
1 Institut Gustave Roussy is the leading cancer research center in Europe and the world’s no. 10 leader for personalized medicine.
The Institute’s work is based on therapy innovation, the development of personalized medicine, healthcare quality and safety, with the patient always at the heart of the care.